On account of the growing number of diabetic patients,
increasing geriatric population, technological advancements in insulin delivery
devices, and rising population exposed to risk factors are leading to the
growth of the human insulin market. The global market generated a revenue of
$42.9 billion in 2017, and it is expected to witness a CAGR of 8.8% during the
forecast period (2018–2023). Human insulin (HI) is synthetic insulin, which
mimics the effects and functionality of natural insulin in humans. It is
generally created by growing the insulin protein in the E. coli bacteria.
In a recent P&S Intelligence research, the human
insulin market is segmented by type, application, and region. Under the
product segment, the market is further divided into HI drugs and delivery
devices. Due to increase in research and development activities for drugs discovery and
manufacture, and high prevalence of diabetes, HI drugs held the larger share
(79.5%) in the market in 2017 in terms of value. Furthermore, the rise in
geriatric population and growth in demand for HI analogs is also pushing the
market progress; analogs and biologics are two categories of the HI drugs
division.
Download Sample of This Research Report:
Globally, North America dominated the human insulin market
in 2017 with 39.2% revenue share. An increase in the number of diabetes
patients contributed in the growth of the domain. The number of diabetic
patients had grown from 108 million to 422 million between 1980 and 2014, and
this number is anticipated to reach 592 million by 2035. As per the
International Diabetes Federation, in 2017, 425 million people aged 20–79
across the globe had diabetes, and this number is projected to reach 629
million by 2045.
Therefore, it is apparent that the steady growth of the
market will give players lucrative opportunities to invest in the research and
development of improved insulin drugs and delivery systems.
